Outlook Refiles Ophthalmic Bevacizumab In US

Follows Withdrawal Of Earlier BLA After FDA Asked For Additional Information

 
• By Dave Wallace
  
Eye fibre optic rainbow
Outlook has refiled its ophthalmic bevacizumab application with the FDA • Source: Shutterstock

More from Biosimilars

More from Products